KR102170609B1 - 박테리아 인공 염색체 - Google Patents

박테리아 인공 염색체 Download PDF

Info

Publication number
KR102170609B1
KR102170609B1 KR1020157033335A KR20157033335A KR102170609B1 KR 102170609 B1 KR102170609 B1 KR 102170609B1 KR 1020157033335 A KR1020157033335 A KR 1020157033335A KR 20157033335 A KR20157033335 A KR 20157033335A KR 102170609 B1 KR102170609 B1 KR 102170609B1
Authority
KR
South Korea
Prior art keywords
cdna
viral
rna
virus
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157033335A
Other languages
English (en)
Korean (ko)
Other versions
KR20160003032A (ko
Inventor
카이 달메이어
요한 나이츠
Original Assignee
카트호리이케 유니버시타이트 로이펜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카트호리이케 유니버시타이트 로이펜 filed Critical 카트호리이케 유니버시타이트 로이펜
Publication of KR20160003032A publication Critical patent/KR20160003032A/ko
Application granted granted Critical
Publication of KR102170609B1 publication Critical patent/KR102170609B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • C12N15/69Increasing the copy number of the vector
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020157033335A 2013-04-26 2014-04-25 박테리아 인공 염색체 Active KR102170609B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1307528.8A GB201307528D0 (en) 2013-04-26 2013-04-26 Bacterial artificial chromosomes
GB1307528.8 2013-04-26
PCT/EP2014/058459 WO2014174078A1 (en) 2013-04-26 2014-04-25 Bacterial artificial chromosomes

Publications (2)

Publication Number Publication Date
KR20160003032A KR20160003032A (ko) 2016-01-08
KR102170609B1 true KR102170609B1 (ko) 2020-10-28

Family

ID=48626864

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157033335A Active KR102170609B1 (ko) 2013-04-26 2014-04-25 박테리아 인공 염색체

Country Status (17)

Country Link
US (2) US10076564B2 (https=)
EP (2) EP2989205B1 (https=)
JP (1) JP6501756B2 (https=)
KR (1) KR102170609B1 (https=)
CN (2) CN120249337A (https=)
AU (1) AU2014259354B2 (https=)
BR (1) BR112015026531B1 (https=)
DK (1) DK2989205T3 (https=)
ES (1) ES2718187T3 (https=)
GB (1) GB201307528D0 (https=)
HU (1) HUE042886T2 (https=)
PL (1) PL2989205T3 (https=)
PT (1) PT2989205T (https=)
SI (1) SI2989205T1 (https=)
TR (1) TR201904215T4 (https=)
WO (1) WO2014174078A1 (https=)
ZA (1) ZA201507795B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716307D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2019204654A1 (en) * 2018-04-18 2019-10-24 Utah State University Compositions and methods for zika virus characterization and vaccine development
GB201814563D0 (en) 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
US20220168412A1 (en) 2019-04-10 2022-06-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese Encephalitis Virus
CN114728054A (zh) 2019-09-13 2022-07-08 勒芬天主教大学 拉沙病毒疫苗
EP4041301A1 (en) 2019-09-13 2022-08-17 Katholieke Universiteit Leuven Chimeric filovirus vaccines
CN114450408A (zh) * 2019-09-25 2022-05-06 鲁汶天主教大学 大载体和用于高产量生产的方法
CA3168673A1 (en) * 2020-02-27 2021-09-02 Kai DALLMEIER Coronavirus vaccines
WO2025012350A1 (en) * 2023-07-11 2025-01-16 Virovet Nv Vectors expressing attenuated rna virus of the family arteriviridae and uses thereof
WO2025171062A1 (en) * 2024-02-06 2025-08-14 The Regents Of The University Of California iMODULON GENE CLUSTERS AND METHODS TO IDENTIFY AND USE SAME

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665600A (en) 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
US5866404A (en) 1995-12-06 1999-02-02 Yale University Yeast-bacteria shuttle vector
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US5874259A (en) * 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector
WO2000034497A2 (en) 1998-12-09 2000-06-15 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
US6472177B1 (en) 2001-04-23 2002-10-29 Wisconsin Alumni Research Foundation Expression vector with dual control of replication and transcription
US6864087B2 (en) * 2001-07-31 2005-03-08 Wisconsin Alumni Research Foundation Method for converting single-copy BAC vectors to conditional high-copy pBAC/oriHC vectors
US20050106733A1 (en) 2001-12-25 2005-05-19 Kenzo Takada Double-stranded cyclic dna capable of proliferating as a bacterial e coli chromosome
WO2004033633A2 (en) 2002-10-04 2004-04-22 Embiosis Pharmaceuticals Compatible host/vector systems for expression of dna
WO2005042014A1 (en) 2003-10-29 2005-05-12 The University Of Queensland West nile virus vaccine
US20050214838A1 (en) 2004-03-10 2005-09-29 Waclaw Szybalski Methods for mapping and sequencing nucleic acids
WO2009053988A1 (en) 2007-10-25 2009-04-30 Ramot At Tel-Aviv University Ltd. Production of bac vectors carrying viral genomes
CN101864442A (zh) 2010-05-19 2010-10-20 江苏省农业科学院 重组火鸡疱疹病毒细菌人工染色体转移载体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Genome Research. 2002,12:1434-1444.
Journal of General Virology, 2006, 87:2263-2268.
Journal of Virology. 2003, 77:6450-6465

Also Published As

Publication number Publication date
AU2014259354B2 (en) 2020-02-27
SI2989205T1 (sl) 2019-05-31
WO2014174078A1 (en) 2014-10-30
CN120249337A (zh) 2025-07-04
EP2989205B1 (en) 2019-01-02
AU2014259354A1 (en) 2015-11-05
EP2989205A1 (en) 2016-03-02
ZA201507795B (en) 2019-07-31
EP3540065A1 (en) 2019-09-18
GB201307528D0 (en) 2013-06-12
US10076564B2 (en) 2018-09-18
CN105229153A (zh) 2016-01-06
ES2718187T3 (es) 2019-06-28
JP2016518132A (ja) 2016-06-23
US20190111125A1 (en) 2019-04-18
BR112015026531A2 (https=) 2017-09-05
PT2989205T (pt) 2019-04-23
PL2989205T3 (pl) 2019-06-28
HUE042886T2 (hu) 2019-07-29
KR20160003032A (ko) 2016-01-08
BR112015026531B1 (pt) 2023-02-07
TR201904215T4 (tr) 2019-04-22
US20160206723A1 (en) 2016-07-21
DK2989205T3 (en) 2019-04-23
JP6501756B2 (ja) 2019-04-17

Similar Documents

Publication Publication Date Title
KR102170609B1 (ko) 박테리아 인공 염색체
TW200924792A (en) A recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a disease caused by KHV/CyHV-3 in Cyorinus carpio carpio or Cyprinus carpio koi
Liu et al. Generation and functional evaluation of a DNA vaccine co-expressing Cyprinid herpesvirus-3 envelope protein and carp interleukin-1 beta
US20250057932A1 (en) Vaccines against infectious diseases caused by positive stranded rna viruses
EP1556493B1 (en) Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof
WO2011118743A1 (ja) 感染性c型肝炎ウイルス高生産hcv変異体及びその利用
Nickols et al. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice
JP2006526393A (ja) フラビウイルスレプリコンパッケージング系
EP4265631A2 (en) Live-attenuated flaviruses with heterologous antigens
EP1650308A1 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
CN114807232A (zh) 一株西尼罗病毒感染性克隆的构建及其应用
NZ741950A (en) Vaccines against hepatitis b virus
AU2004245578A1 (en) Flavivirus replicon packaging system

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200623

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200907

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201021

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241016

Start annual number: 5

End annual number: 5